Every letter we have printed

I am sixty-eight, I have lost nineteen kilograms over fourteen months, and my consultant has twice told me my lean mass is fine on the basis of a handheld bioimpedance device in the clinic corridor. Having read your piece on what that device measures, I am no longer sure what I have been reassured about.

Small correction to your table: the S-LiTE exercise prescription was two supervised group sessions and two individual sessions weekly, not two sessions in total. The distinction matters because "add some exercise" is not what was tested.

I stopped treatment fifteen weeks ago and my panel is worse than I expected. I had a panel at five weeks that looked fine and I had assumed I had escaped. Your point about the twelve-week timing was the explanation nobody offered me.

My eGFR has risen from 71 to 84 over fourteen months of treatment and I have lost twenty-six kilograms. My prescriber described this as the drug protecting my kidneys. Having read your creatinine section, I suspect it is mostly that I have less muscle. Which of us is right?

You give the reference change value for ALT as about sixty per cent, which strikes me as so large as to make routine monitoring of it pointless. Is that your position?

As a biomedical scientist I would add one point to your reference-interval section: many laboratories do not derive their own intervals at all. They adopt the manufacturer interval for the platform, which was established in a population that may have nothing to do with the one being tested. The interval on the report can be a document about a different country.

My HbA1c was 6.1 before starting and 6.0 after four months. My clinic recorded this as no improvement in glycaemic control. My continuous monitor says my average glucose fell by a fifth over the same period. Which is measuring what?

A small thing: you write "class B GPCR" and then "secretin-like receptor" as though these were different classifications. They are the same family under two naming conventions, and the piece would be clearer if it said so.

I have been on treatment for fourteen months and stopped losing weight at month eleven. Your piece says this is energy balance rather than receptor desensitisation. I would find that easier to accept if anybody had explained it to me at the start rather than after I had spent two months assuming the drug had stopped working.

VendorInvestigate does not measure anything and you have grouped it with three laboratories under the heading independent testing. That is exactly the conflation your article says the market makes.

You recommend writing the concentration on the vial. I would add: write it on the box as well. My vial label came off in the fridge and I lost the only record of what diluent volume I had used.

I have shipped temperature-sensitive material commercially for eleven years and your coolant arithmetic is right but generous. You assume the pack starts fully frozen. In practice packs are pulled from a freezer that is opened forty times a day, and a pack that starts at minus four with a soft core has lost a fair share of its budget before the box is closed.

You say no company reports residual moisture. I obtained a figure from a supplier last year without difficulty, on request, so the data exists in at least some cases. The problem may be less that it is not measured than that it is not printed.

Eleven days in customs, and you describe it as a structural feature rather than a scandal. Why the restraint? A shipper advertising a cold chain that demonstrably does not survive a routine examination is making a claim it cannot support.

Your section on freezing reconstituted solution stops short of the obvious question, which I will therefore ask. If a phosphate buffer shifts pH substantially on freezing, does that not mean the freezer is actively worse than the refrigerator for a buffered formulation, rather than merely unproven?

Why did you submit only two vials for sterility testing when the whole article argues that the sample size is the problem? Two is worse than twenty by exactly the argument you make.

On multiple-dose closures: the puncture budget you refer to is generally in single figures for a standard lyophilisation stopper, and the qualification uses a new needle each time. Anybody reusing a needle through the same entry point is outside the data entirely.

You keep saying you are criticising documentation and not honesty. I think that distinction is doing more work than it can bear. If a company knows buyers read a purity certificate as a safety document and issues one anyway, the omission is doing something.

I photograph every cake now because of an earlier piece of yours, and last month it paid for itself. Two vials from the same box, one a proper matte plug and one a collapsed glassy disc. The supplier replaced both without argument when I sent the photographs.

You write that recombinant factor C is insensitive to the glucan branch of the cascade. It would be worth adding why anybody cares: cellulose filter media and certain paper wrappings shed glucans, and a laboratory that has chased a false positive through three repeat assays will never willingly go back to a reagent that responds to them.

You keep saying you are criticising documentation and not honesty. I think that distinction is doing more work than it can bear. If a company knows buyers read a purity certificate as a safety document and issues one anyway, the omission is doing something.

The claim that stopping does not leave you worse off than baseline is a group-level claim about trial arms. Individuals can and do overshoot. Your phrasing invites readers to conclude otherwise.

I take this for kidney disease, not for weight. Every piece of writing I encounter about stopping is about the weight coming back. It has taken me a year to find anybody willing to say plainly that the renal benefit accrued over years of treatment and nobody has tested what happens if I stop.

Your fortnightly arithmetic table is correct but I think it understates the practical point. A fourfold peak-to-trough swing is not merely lower average exposure; it is a different drug experience, with the last few days of each cycle spent at a concentration the person has effectively titrated off.

Three months after stopping, my HbA1c had barely moved and I concluded I had got away with it. Six months after stopping, it was back where it started. Your point about the lag is the single most useful sentence I have read on this subject.

Your piece describes tapering as pharmacologically pointless and then spends three paragraphs making a case for it. Pick one.

Your piece describes tapering as pharmacologically pointless and then spends three paragraphs making a case for it. Pick one.

I lost access for eleven weeks during the shortage, restarted at the dose I had been on because nobody told me otherwise, and spent a fortnight unable to keep food down. I had been on that dose for seven months without difficulty. Reading your resumption section was the first time anybody explained it.

Your figures show diarrhoea at thirty-two per cent and constipation at twenty-three per cent in the same trial arm. I assumed one of these was an error until your mechanism section. It would be worth putting that explanation before the table rather than after it.

You draw a distinction between retest date and expiry date and then say suppliers use the wrong word. Which word do you think they should use, given that most of them have no study behind either?

I would add one omission to your list. Nobody states the headspace gas. Nitrogen-backfilled vials and air-sealed vials behave differently for any oxidation-prone sequence, and it is a single word on a certificate.

Correction to your HbA1c section. You write that chronic kidney disease lowers HbA1c through shortened erythrocyte survival. It can also raise measured values on some assay platforms through carbamylated haemoglobin interference. The net direction depends on the method.

Your piece assumes readers have a clinician ordering panels for them. A great many of us are buying our own, from services that supply an interval, a flag and nothing else. The apparatus you describe is not available to us at all.

My eGFR has risen from 71 to 84 over fourteen months of treatment and I have lost twenty-six kilograms. My prescriber described this as the drug protecting my kidneys. Having read your creatinine section, I suspect it is mostly that I have less muscle. Which of us is right?

I stopped treatment fifteen weeks ago and my panel is worse than I expected. I had a panel at five weeks that looked fine and I had assumed I had escaped. Your point about the twelve-week timing was the explanation nobody offered me.

As a biomedical scientist I would add one point to your reference-interval section: many laboratories do not derive their own intervals at all. They adopt the manufacturer interval for the platform, which was established in a population that may have nothing to do with the one being tested. The interval on the report can be a document about a different country.

A quibble about depyrogenation. You imply an operation describing autoclaving alone has skipped a step, but depyrogenation of glass is only necessary if the incoming glass carries endotoxin. Vials supplied ready-to-use from a component manufacturer arrive already depyrogenated and certified as such.

The statistics section is the part of this I will be sending to people. I had assumed a passed sterility test meant something about the batch. It had not occurred to me that a batch with one contaminated vial in a hundred passes four times out of five.

You write that recombinant factor C is insensitive to the glucan branch of the cascade. It would be worth adding why anybody cares: cellulose filter media and certain paper wrappings shed glucans, and a laboratory that has chased a false positive through three repeat assays will never willingly go back to a reagent that responds to them.

Your endotoxin table gives vial 12 at 112 EU per vial and then declines to say whether that is dangerous. I understand why. It is still frustrating to read a figure of that size next to the sentence "arithmetic, not a safety assessment".